Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eyevance gains global license to Novartis' ophthalmic suspensions

Executive Summary

Eyevance Pharmaceuticals LLC licensed exclusive worldwide rights to Novartis AG's TobraDex ST (tobramycin 0.3%/dexamethasone 0.05%) and Natacyn (natamycin 5%) ophthalmic suspensions.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • Reverse Licensing
    • Marketing-Licensing

Related Companies